CRGX Stock Overview
A clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CARGO Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.67 |
| 52 Week High | US$33.92 |
| 52 Week Low | US$13.56 |
| Beta | 0 |
| 11 Month Change | -16.49% |
| 3 Month Change | -6.31% |
| 1 Year Change | 8.47% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 21.61% |
Recent News & Updates
Shareholder Returns
| CRGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.9% | 2.4% | 0.5% |
| 1Y | 8.5% | 15.6% | 30.7% |
Return vs Industry: CRGX underperformed the US Biotechs industry which returned 15.6% over the past year.
Return vs Market: CRGX underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| CRGX volatility | |
|---|---|
| CRGX Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRGX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRGX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 170 | Gina Chapman | cargo-tx.com |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets.
CARGO Therapeutics, Inc. Fundamentals Summary
| CRGX fundamental statistics | |
|---|---|
| Market cap | US$813.31m |
| Earnings (TTM) | -US$154.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.3x
P/E RatioIs CRGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRGX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$154.14m |
| Earnings | -US$154.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CRGX perform over the long term?
See historical performance and comparison